Lysomal Therapeutics


Lysosomal Therapeutics Inc. (LTI) is dedicated to innovative small-molecule research and development in the field of neurodegeneration, yielding new treatment options for patients with severe neurological diseases. Company strategy leverages the clinically-validated link between lysosome-based genetic disorders and neurodegenerative diseases to establish a unique and effective molecular platform for novel drug discovery. LTI’s lead program targets Gaucher-related neurodegeneration, Parkinson’s disease and other synucleinopathies.

Other investors include Atlas Ventures, Hatteras Venture Partners, Sanofi-Genzyme BioVentures, Roche Venture Fund and Partners Innovation Fund.